T cell receptor and major histocompatibility complex molecule (TCR and MHC)

The **T cell receptor (TCR)** is a multimeric protein complex on the surface of T cells responsible for recognizing peptide antigens presented in the context of major histocompatibility complex (**MHC**) molecules on antigen-presenting or target cells[7][1][3]. The interaction between the TCR and peptide–MHC (pMHC) complex initiates T cell activation through a complex signaling cascade[2][4][6]. MHC class I molecules present peptides derived from intracellular proteins to CD8+ cytotoxic T cells, while MHC class II molecules present peptides from extracellular proteins to CD4+ helper T cells[4][2]. Recognition is highly specific and subject to **MHC restriction**, meaning a given TCR only recognizes antigenic peptide in the context of a particular MHC allele[3][5][9]. The biological significance of TCR–MHC interactions underpins adaptive immunity, immune surveillance against pathogens and tumors, as well as roles in autoimmunity and transplant rejection[3][6][7]. Both TCR and MHC molecules are highly polymorphic, their diversity being a central feature of population-level resistance to pathogens[3][1]. **Note:** There is something incorrect or problematic about this "target" as defined in your query: "T cell receptors and MHC molecules" is not a single, specific molecular target, but refers to the **pairwise interaction between two distinct protein families** (T cell receptors and MHC molecules)[7][1][3]. For structured drug discovery or biomarker purposes, these are almost always referenced separately (e.g., a particular TCR, or MHC class I molecule HLA-A2). Therefore, **is_incorrect: true**. Consider refining your target to either "T cell receptor" or a specific "MHC molecule" for more precise information.

Other names

TCRMHCTCR–MHC complexpeptide–MHC complexT cell antigen receptor and MHCTCR–pMHC

Blockade of TCR signaling (immunosuppressants); Augmentation of TCR–pMHC interaction (T cell therapies); Immune checkpoint blockade (enhancing TCR-mediated killing); Redirection of TCR specificity (engineered T cell therapies)